Research programme: cancer therapies - H3 BiomedicineAlternative Names: SF3B1 inhibitors - H3 Biomedicine; SF3B1 modulator - H3 Biomedicine; Splicing factor inhibitor - H3 Biomedicine; Splicing inhibitors - H3 Biomedicine
Latest Information Update: 25 Jul 2016
At a glance
- Originator H3 Biomedicine
- Class Antineoplastics
- Mechanism of Action Phosphoprotein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer